Investing.com - Financial Markets Worldwide

OncoTherapy Science Inc (4564)

Tokyo
Symbol
Exchange
Currency
4564·Tokyo·JPY
30O·Frankfurt·EUR
Currency in JPY
33.0
+4.0(+13.79%)
Closed·
4564 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Unlock Value
Day's Range
30.033.0
52 wk Range
21.064.0
Key Statistics
Edit
Bid/Ask
29.00 / 30.00
Prev. Close
29
Open
30
Day's Range
30-33
52 wk Range
21-64
Volume
21.2M
Average Volume (3m)
5.02M
1-Year Change
6.45%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4564 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 10
Significant return over the last week
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

OncoTherapy Company Profile

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
47
Market
Japan

Compare 4564 to Peers and Sector

Metrics to compare
4564
Peers
Sector
Relationship
P/E Ratio
−11.2x−6.4x−0.5x
PEG Ratio
−0.23−0.100.00
Price/Book
12.5x4.4x2.6x
Price / LTM Sales
12.1x50.9x3.1x
Upside (Analyst Target)
-61.8%46.1%
Fair Value Upside
Unlock11.5%6.9%Unlock

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.34 / --
Revenue / Forecast
187.00M / --
EPS Revisions
a
a
Unlock
Last 90 days

4564 Income Statement

FAQ

What Is the OncoTherapy (4564) Stock Price Today?

The OncoTherapy stock price today is 33.00.

What Stock Exchange Does OncoTherapy Trade On?

OncoTherapy is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for OncoTherapy?

The stock symbol for OncoTherapy is "4564."

What Is the OncoTherapy Market Cap?

As of today, OncoTherapy market cap is 9.10B.

What Is OncoTherapy's Earnings Per Share (TTM)?

The OncoTherapy EPS (TTM) is -3.12.

When Is the Next OncoTherapy Earnings Date?

OncoTherapy will release its next earnings report on 31 Jul 2025.

From a Technical Analysis Perspective, Is 4564 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has OncoTherapy Stock Split?

OncoTherapy has split 2 times.

How Many Employees Does OncoTherapy Have?

OncoTherapy has 47 employees.

What is the current trading status of OncoTherapy (4564)?

As of 12 Jul 2025, OncoTherapy (4564) is trading at a price of 33.00, with a previous close of 29.00. The stock has fluctuated within a day range of 30.00 to 33.00, while its 52-week range spans from 21.00 to 64.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.